Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > February 26, 2024
Daily News
February 26, 2024
- Chugai Tapping Wearable to Objectively Gauge Pain, First Eyes Endometriosis Trial
February 26, 2024
- Pneumococcal Jabs Help Curb Pediatric Emergency Visits: Pediatrician
February 26, 2024
- Japan Panel Backs Approval of Takeda’s Acquired Hemophilia A Drug
February 26, 2024
- Novel Antibiotic Fetroja Approved in Taiwan: Shionogi
February 26, 2024
- Maruho’s China Subsidiary Now Up and Running
February 26, 2024
- Economic Terms for Obesity Drug Deal Disclosed by Lilly: Chugai
February 26, 2024
- As Wegovy Hits Japan Market, Novo Re-Stresses Need for Proper Use
February 26, 2024
- Drug Comparisons in Promotional Activities Allowed under 4 Conditions: MHLW
February 26, 2024
Japan will overhaul its R&D tax credit regime in its FY2026 reform, introducing a new strategic category alongside existing frameworks.…
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…